Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity

doi:10.1210/en.2016-1665

Paper

Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity

Published 2017 · Clinton T. Elfers, C. Roth

Endocrinology

Q1 SJR score

12

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Hypothalamic lesions or deficient melanocortin (MC) signaling via MC4 receptor (MC4r) mutations often lead to hyperphagia and severe treatment-resistant obesity. We tested the methionine aminopeptidase 2-inhibitor beloranib (ZGN-440) in 2 male rat models of obesity, one modeling hypothalamic obesity with a combined medial hypothalamic lesion (CMHL) and the other modeling a monogenic form of obesity with MC4r mutations (MC4r knockout [MC4rKO]). In CMHL rats (age 3 months), postsurgery excess weight gain was significantly inhibited (ZGN-440, 0.2 ± 0.7 g/d; vehicle, 3.8 ± 0.6 g/d; P < 0.001) during 12 days of ZGN-440 treatment (0.1 mg/kg daily subcutaneously) together with a 30% reduction of daily food intake vs vehicle injection. In addition, ZGN-440 treatment improved glucose tolerance and reduced plasma insulin, and circulating levels of α-melanocyte stimulating hormone were increased. Serum lipid levels did not differ significantly in ZGN-440-treated vs vehicle-treated rats. Similar results were found in MC4rKO rats: ZGN-440 treatment (14-21 d) was associated with significant reductions of body weight gain (MC4rKO, -1.7 ± 0.6 vs 2.8 ± 0.4 g/d; lean wild-type controls, -0.7 ± 0.2 vs 1.7 ± 0.7 g/d; ZGN-440 vs vehicle, respectively), reduction of food intake (MC4rKO, -28%; lean controls, -7.5%), and insulin resistance, whereas circulating levels of interleukin-1β did not change. In both obesity models, body temperature and locomotor activity were not affected by ZGN-440 treatment. In conclusion, the robust reduction of body weight in response to ZGN-440 observed in rats with severe obesity is related to a strong reduction of food intake that is likely related to changes in the central regulation of feeding.

Non-RCT

Animal Study

Rigorous Journal

Study Snapshot

Beloranib effectively reduces excess weight and hyperphagia in rats with severe obesity, likely due to changes in central feeding regulation.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity

References

Citations

Covalent drug – An emerging framework for targeted drug development

Covalent drugs show promise for drug discovery, targeting various proteins and offering heightened selectivity, lower doses, and the degradation of previously undruggable proteins, potentially improving treatment options.

Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon

Recent obesity drug developments show promise for successful interventions in people with hypothalamic obesity related to hypothalamic injury.

Current pharmacological approaches in obesity treatment

Current obesity treatments include short-term and long-term drugs, but lifestyle changes are necessary for effective and safe management.

Treatment of Acquired Hypothalamic Obesity: Now and the Future

Current therapies for acquired hypothalamic obesity in children and young people show modest and variable results, requiring novel or combined approaches for credible and sustained weight loss.

MetAP2 Inhibitor Treatment of High-Fat and -Fructose Fed Dogs: Impact on the Response to Oral Glucose Ingestion and a Hyperinsulinemic Hyperglycemic Clamp.

Fumagillin improves glucose tolerance and net hepatic glucose uptake in high-fat and fructose-fed dogs, suggesting MetAP2 inhibitors have potential for improving glycemic control in prediabetes and diabetes.